trial profile
DESCRIPTION
Trial profile. John A Dormandy et al. Lancet 2005;366:1279-89. Baseline characteristics. John A Dormandy et al. Lancet 2005;366:1279-89. Macrovascular morbidity at study entry and associated medications. John A Dormandy et al. Lancet 2005;366:1279-89. - PowerPoint PPT PresentationTRANSCRIPT
Trial profile
John A Dormandy et al. Lancet 2005;366:1279-89
Baseline characteristics
John A Dormandy et al. Lancet 2005;366:1279-89
Macrovascular morbidity at study entry and associated medications
John A Dormandy et al. Lancet 2005;366:1279-89
Kaplan-Meier curve of time to primary endpoint
John A Dormandy et al. Lancet 2005;366:1279-89
Kaplan-Meier curve of time to main secondary endpoint
John A Dormandy et al. Lancet 2005;366:1279-89
Numbers of first events contributing to the primary composite and main secondary endpoints
John A Dormandy et al. Lancet 2005;366:1279-89
Effect of pioglitazone and placebo on each component of the primary endpoint
John A Dormandy et al. Lancet 2005;366:1279-89
Hazard associated with relevant baseline characteristics for the main secondary
endpoint
John A Dormandy et al. Lancet 2005;366:1279-89
Change in proportion of patients using concomitant medications
John A Dormandy et al. Lancet 2005;366:1279-89
Kaplan-Meier curve of time to permanent insulin use
John A Dormandy et al. Lancet 2005;366:1279-89
Change in laboratory data from baseline to final visit
John A Dormandy et al. Lancet 2005;366:1279-89
Serious adverse event summary
John A Dormandy et al. Lancet 2005;366:1279-89
Reports of heart failure
John A Dormandy et al. Lancet 2005;366:1279-89